Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Other financing activities: 2023-2025

Historic Other financing activities for Cellebrite DI (CLBT) over the last 1 years, with Sep 2025 value amounting to $15.3 million.

  • Cellebrite DI's Other financing activities rose 69.06% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.7 million, marking a year-over-year increase of 60.76%. This contributed to the annual value of $30.6 million for FY2024, which is 60.94% up from last year.
  • Per Cellebrite DI's latest filing, its Other financing activities stood at $15.3 million for Q3 2025, which was up 74.41% from $8.8 million recorded in Q1 2025.
  • Over the past 5 years, Cellebrite DI's Other financing activities peaked at $15.3 million during Q3 2025, and registered a low of $4.9 million during Q3 2023.
  • Moreover, its 3-year median value for Other financing activities was $6.6 million (2024), whereas its average is $7.9 million.
  • Data for Cellebrite DI's Other financing activities shows a peak YoY soared of 85.52% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Cellebrite DI's Other financing activities stood at $5.1 million in 2023, then rose by 29.55% to $6.6 million in 2024, then surged by 69.06% to $15.3 million in 2025.
  • Its last three reported values are $15.3 million in Q3 2025, $8.8 million for Q1 2025, and $6.6 million during Q4 2024.